Back to Search

MACE ROTHENBERG, MD

MD

Medical Oncology Physician

NPI: 1336231752Individual

Specialties, Licenses & Credentials

Medical Oncology PhysicianPrimary

Internal Medicine — Medical Oncology

Code: 207RX0202X

MD30072(TN)

Research & Publications (20)

Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study.
PMID 18550577·Ann Oncol·2008
3-trial
Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma.
PMID 16361624·J Clin Oncol·2005
3-trial
Current status of second-line therapy for metastatic colorectal cancer.
PMID 15212701·Clin Colorectal Cancer·2004
6-review
Phase II trial of vinorelbine for relapsed ovarian cancer: a Southwest Oncology Group study.
PMID 15581954·Gynecol Oncol·2004
3-trial
Improving the evaluation of new cancer treatments: challenges and opportunities.
PMID 12671669·Nat Rev Cancer·2003
6-review
Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial.
PMID 12775730·J Clin Oncol·2003
3-trial
Combined intraperitoneal and intravenous chemotherapy for women with optimally debulked ovarian cancer: results from an intergroup phase II trial.
PMID 12663720·J Clin Oncol·2003
3-trial
Phase II trial of 5-fluorouracil plus eniluracil in patients with advanced pancreatic cancer: a Southwest Oncology Group study.
PMID 12377645·Ann Oncol·2002
3-trial
Current status of capecitabine in the treatment of colorectal cancer.
PMID 12520635·Oncology (Williston Park)·2002
6-review
Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel.
PMID 11559717·J Clin Oncol·2001
8-other
Irinotecan (CPT-11): recent developments and future directions--colorectal cancer and beyond.
PMID 11161230·Oncologist·2001
6-review
Phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer: a Southwest Oncology Group trial (SWOG-9326).
PMID 11531286·Gynecol Oncol·2001
3-trial
Local B cells and IgE production in the oesophageal mucosa in eosinophilic oesophagitis.
PMID 19528036·Gut·2010
8-other
Biology and treatment of eosinophilic esophagitis.
PMID 19596009·Gastroenterology·2009
6-review
Eosinophil viability is increased by acidic pH in a cAMP- and GPR65-dependent manner.
PMID 19641187·Blood·2009
7-preclinical
Murine model of hypereosinophilic syndromes/chronic eosinophilic leukemia.
PMID 19494514·Int Arch Allergy Immunol·2009
6-review
Voice onset time versus articulatory modeling for stop consonants.
PMID 19513923·Logoped Phoniatr Vocol·2009
8-other
CCR3 is a target for age-related macular degeneration diagnosis and therapy.
PMID 19525930·Nature·2009
7-preclinical
Bone marrow cell derived arginase I is the major source of allergen-induced lung arginase but is not required for airway hyperresponsiveness, remodeling and lung inflammatory responses in mice.
PMID 19486531·BMC Immunol·2009
7-preclinical
Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group.
PMID 19581537·J Clin Oncol·2009
3-trial

Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.

Contact & Hours

Address
3601 TVC
NASHVILLE, TN 37232

Location

Practice Location

3601 TVC, NASHVILLE, TN
(615) 322-3000

Quick Facts

NPI
1336231752
Entity Type
Individual
Gender
Male
Medicare
Not confirmed
Specialties
1
Locations
1
Publications
20

Are you this provider?

Claim Your Profile